Literature DB >> 21817964

Vitreous hemorrhage complicating intravitreal tissue plasminogen activator and pneumatic displacement of submacular hemorrhage.

Tsung-Tien Wu1, Ya-Hsin Kung, May-Ching Hong.   

Abstract

PURPOSE: To evaluate the clinical factors associated with vitreous hemorrhage (VH) complicating intravitreal tissue plasminogen activator and pneumatic displacement of submacular hemorrhage, and analyze visual outcomes.
METHODS: In this retrospective, comparative study, 120 consecutive eyes underwent intravitreal tissue plasminogen activator (50 μg) and perfluoropropane (0.3 mL) injection for submacular hemorrhage secondary to different causes. We recorded their demographic data, visual acuity, complications, and further treatment after VH. Two groups created according to the occurrence of VH were compared to identify possible risk factors.
RESULTS: Breakthrough VH occurred in 18 eyes (15%). The size of submacular hemorrhage was significantly positively related to the occurrence of VH (P for trend <0.001). Among etiology, idiopathic polypoidal choroidal vasculopathy (IPCV) was associated with a significantly higher incidence of VH (odds ratio, 15.63; 95% confidence interval, 2.30-106.15; P = 0.005). Age-related macular degeneration was much less likely than other causes to result in VH (odds ratio, 0.121; 95% confidence interval, 0.023-0.642; P = 0.013). Best and final visual acuity improved significantly from initial visual acuity in both groups (P < 0.05).
CONCLUSION: A large area of submacular hemorrhage (≥10 disk areas) and IPCV were risk factors for VH after injection. The occurrence of VH did not affect final visual outcome.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21817964     DOI: 10.1097/IAE.0b013e31822528c8

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  6 in total

1.  Intravitreal anti-vascular endothelial growth factor monotherapy for large submacular hemorrhage secondary to neovascular age-related macular degeneration.

Authors:  H S Kim; H J Cho; S G Yoo; J H Kim; J I Han; T G Lee; J W Kim
Journal:  Eye (Lond)       Date:  2015-08-14       Impact factor: 3.775

2.  Visual outcomes of vitrectomy for polypoidal choroidal vasculopathy-related breakthrough vitreous haemorrhage.

Authors:  H-C Lin; C-H Yang; C-M Yang
Journal:  Eye (Lond)       Date:  2014-06-13       Impact factor: 3.775

3.  The effect of initial intravitreal tissue plasminogen activator and gas injection on vision improvement in patients with submacular haemorrhage associated with age-related macular degeneration.

Authors:  Seung Ha Lee; Sang Joon Lee; Yong Il Shin; Hyung Bin Lim; Jung Yeul Kim; Yong Seop Han; Ki Yup Nam
Journal:  Eye (Lond)       Date:  2021-01-09       Impact factor: 4.456

4.  Risk factors for breakthrough vitreous hemorrhage after intravitreal tissue plasminogen activator and gas injection for submacular hemorrhage associated with age related macular degeneration.

Authors:  Jun Hyun Lim; Yong Seop Han; Sang Joon Lee; Ki Yup Nam
Journal:  PLoS One       Date:  2020-12-03       Impact factor: 3.240

Review 5.  Polypoidal choroidal vasculopathy: an update on therapeutic approaches.

Authors:  Raymond L M Wong; Timothy Y Y Lai
Journal:  J Ophthalmic Vis Res       Date:  2013-10

6.  Risk factors for breakthrough vitreous hemorrhage after intravitreal anti-VEGF injection in age-related macular degeneration with submacular hemorrhage.

Authors:  Yong-Il Shin; Jae-Yun Sung; Min Sagong; Young-Hoon Lee; Young-Joon Jo; Jung-Yeul Kim
Journal:  Sci Rep       Date:  2018-07-12       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.